Nonmyeloablative Allogeneic Transplant
Allogeneic transplant from a matched sibling for the treatment of a variety of illnesses including bone marrow failure states, leukemias, myelodysplastic or myeloproliferative syndromes, lymphoma, or myeloma using a nonmyeloablative preparative regimen.
Aplastic Anemia|Paroxysmal Nocturnal Hemoglobinuria|Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Myelodysplastic Syndrome|Chronic Myelogenous Leukemia|Chronic Lymphocytic Leukemia|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma|Multiple Myeloma|Waldenstrom Macroglobulinemia|Breast Cancer|Renal Cell Carcinoma|Melanoma|Sarcoma|Ovarian Cancer|Thymoma
PROCEDURE: Nonmyeloablative Allogeneic Transplant|PROCEDURE: Nonmyeloablative Allogeneic Transplant
Engraftment, Evaluation of engraftment of donor stem cells by bone marrow examinations at days 30, 100, and 360 after transplant., One year
Graft-versus-host disease, Assess the incidence and severity of acute and/or chronic GVHD for patients transplanted on this protocol., One year
same